bluebird bio (BLUE) Stock Forecast, Price & News

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 11 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio or view top-rated stocks.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for bluebird bio.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Monday, May, 9th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by $0.10. The biotechnology company had revenue of $1.95 million for the quarter, compared to analyst estimates of $0.17 million. bluebird bio had a negative trailing twelve-month return on equity of 111.73% and a negative net margin of 2,183.15%. The company's quarterly revenue was up 117.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.07) earnings per share.
View bluebird bio's earnings history.

What price target have analysts set for BLUE?

15 brokerages have issued 1 year price targets for bluebird bio's shares. Their forecasts range from $3.00 to $23.00. On average, they anticipate bluebird bio's stock price to reach $11.75 in the next twelve months. This suggests a possible upside of 259.3% from the stock's current price.
View analysts' price targets for bluebird bio or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:

• Mr. Andrew Obenshain, Pres, CEO & Director (Age 47) (LinkedIn Profile)
• Mr. Jason F. Cole Esq., Chief Strategy & Financial Officer (Age 49, Pay $619.8k)
• Mr. Kasra Kasraian, Sr. VP of Technical Devel. & Operations
• Ms. Jessica Whitten, VP, Global Controller & Chief Accounting Officer (Age 45) (LinkedIn Profile)
• Ms. Elizabeth Pingpank, Director of Corp. Communications
• Sarah Alspach, Chief Communications Officer
• Ms. Kathleen A. Wilkinson, Chief People Officer (Age 50)
• Dr. Liviu Niculescu M.D., Ph.D., Sr. VP of Global Medical Affairs
• Ms. Melissa Bonner, Sr. VP of Research
• Ms. Anne-Virginie Eggimann M.Sc., Chief Regulatory Officer

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

Who are some of bluebird bio's key competitors?

Some companies that are related to bluebird bio include Recursion Pharmaceuticals (RXRX), GreenLight Biosciences (GRNA), REGENXBIO (RGNX), Sana Biotechnology (SANA), Alector (ALEC), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Anavex Life Sciences (AVXL), NanoString Technologies (NSTG), Replimune Group (REPL), iTeos Therapeutics (ITOS), Osiris Therapeutics (OSIR), Coherus BioSciences (CHRS), Sorrento Therapeutics (SRNE) and Sangamo Therapeutics (SGMO).
View all of BLUE's competitors.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (18.41%), Vanguard Group Inc. (8.30%), BlackRock Inc. (8.17%), Goldman Sachs Group Inc. (2.93%), JPMorgan Chase & Co. (2.61%) and Renaissance Technologies LLC (1.32%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly and William D Baird III.
View institutional ownership trends for bluebird bio.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., Citigroup Inc., Principal Financial Group Inc., Group One Trading L.P., BlackRock Inc., Mirae Asset Global Investments Co. Ltd., and BNP Paribas Arbitrage SA. Company insiders that have sold bluebird bio company stock in the last year include Andrew Obenshain, Jason Cole, Jessica Whitten, and Nick Leschly.
View insider buying and selling activity for bluebird bio or view top insider-selling stocks.

Which major investors are buying bluebird bio stock?

BLUE stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Federated Hermes Inc., Goldman Sachs Group Inc., UBS Group AG, Healthcare of Ontario Pension Plan Trust Fund, PDT Partners LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for bluebird bio or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $3.27.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $233.65 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819.38 million in net income (profit) each year or ($10.54) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 518 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (339) 499-9300 or via email at [email protected].